Biotechnology techniques are increasingly being incorporated into modern
clinical practice. In recent years the focus was on the cell production
of diagnostic and therapeutic substances in vitro, and is now shifting
to the use of cells to provide therapies for the treatment of diseases
for which there is, as yet, no cure.
Hybrid Organ provides tools, procedures and technologies for innovative
bioreactor applications. With the conversion of biotechnological knowledge
into new medical products and services, Hybrid Organ's technology platform
and product families make an essential contribution to the further development
of tissue engineering methods and hybrid organ replacements in regenerative
Hybrid Organ takes an integrative approach, developing bioreactors along
with the necessary components such as pump/control systems, and also offering
clinical services in order to facilitate clinical patient treatment, including
the compilation of clinical appliance data - a package we see as having
a significant strategic advantage.
New and additional areas of activity are continuously reviewed with a
view to extending our business activities.
The company's scientific base provides a source of further innovations
and has been expanded through the involvement, contributed know-how and
enthusiasm of Prof. Peter Neuhaus and the Charité Institute of
Through the strategic cooperation with the Biomedical Research Center
of the Humboldt University Berlin and the Charité’s Transplantation
Center, Hybrid Organ is well positioned within a supportive biotech cluster.
This innovative climate provides a broad base of intellectual resources
and facilitates the identification of promising new developments. Hybrid
Organ’s current R&D projects include a ceramic foam bioreactor
for blood stem cells, and a flat membrane bioreactor for skin cells.